Inhibikase Therapeutics | 8-K: Current report
06:11 ET
Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Apr 15 16:14 ET
Inhibikase Therapeutics | 8-K/A: Current report (Amendment)
Apr 2 17:17 ET
Inhibikase Therapeutics | 8-K: Current report
Feb 7 08:01 ET
Inhibikase Therapeutics | 8-K: Current report
Feb 1 16:14 ET
Inhibikase Therapeutics | 8-K: Current report
Jan 16 00:00 ET
Inhibikase Therapeutics | 8-K: Current report
Sep 20, 2023 11:23 ET
Inhibikase Therapeutics | 8-K: Current report
Jul 17, 2023 17:29 ET
Inhibikase Therapeutics | 8-K: Current report
Jun 29, 2023 12:15 ET
Inhibikase Therapeutics | 8-K: Current report
Jun 28, 2023 07:08 ET
Inhibikase Therapeutics | DEFA14A: Others
May 12, 2023 16:16 ET
Inhibikase Therapeutics | DEF 14A: Definitive proxy statements
May 5, 2023 16:31 ET
Inhibikase Therapeutics | PRE 14A: Preliminary proxy statement not related to a contested matter or merger/acquisition
Apr 21, 2023 16:30 ET
Inhibikase Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Mar 31, 2023 16:11 ET
Inhibikase Therapeutics | 8-K: Current report
Mar 22, 2023 16:04 ET
Inhibikase Therapeutics | 8-K: Current report
Mar 13, 2023 17:26 ET
Inhibikase Therapeutics | 8-K: Current report
Mar 6, 2023 16:55 ET
Inhibikase Therapeutics | S-1: General form for registration of securities under the Securities Act of 1933
Feb 1, 2023 21:02 ET
Inhibikase Therapeutics | 8-K: Current report
Jan 26, 2023 16:02 ET
Inhibikase Therapeutics | 8-K: Current report
Jan 25, 2023 09:00 ET
No Data
No Data